These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27683125)

  • 1. Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.
    Kim Y; Kobayashi E; Kubota D; Suehara Y; Mukaihara K; Akaike K; Ito A; Kaneko K; Chuman H; Kawai A; Kitano S
    Oncotarget; 2016 Oct; 7(43):70832-70844. PubMed ID: 27683125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.
    Bean GR; Kremer JC; Prudner BC; Schenone AD; Yao JC; Schultze MB; Chen DY; Tanas MR; Adkins DR; Bomalaski J; Rubin BP; Michel LS; Van Tine BA
    Cell Death Dis; 2016 Oct; 7(10):e2406. PubMed ID: 27735949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.
    Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF
    Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
    McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
    BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
    Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
    Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
    Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
    Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino Acid Uptake Measured by [
    Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
    Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
    [No Abstract]   [Full Text] [Related]  

  • 10. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
    Delage B; Luong P; Maharaj L; O'Riain C; Syed N; Crook T; Hatzimichael E; Papoudou-Bai A; Mitchell TJ; Whittaker SJ; Cerio R; Gribben J; Lemoine N; Bomalaski J; Li CF; Joel S; Fitzgibbon J; Chen LT; Szlosarek PW
    Cell Death Dis; 2012 Jul; 3(7):e342. PubMed ID: 22764101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment.
    Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA
    Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy.
    Long Y; Tsai WB; Wang D; Hawke DH; Savaraj N; Feun LG; Hung MC; Chen HH; Kuo MT
    Cancer Lett; 2017 Mar; 388():54-63. PubMed ID: 27913198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argininosuccinate synthetase 1 contributes to gastric cancer invasion and progression by modulating autophagy.
    Tsai CY; Chi HC; Chi LM; Yang HY; Tsai MM; Lee KF; Huang HW; Chou LF; Cheng AJ; Yang CW; Wang CS; Lin KH
    FASEB J; 2018 May; 32(5):2601-2614. PubMed ID: 29401583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.
    Kremer JC; Prudner BC; Lange SES; Bean GR; Schultze MB; Brashears CB; Radyk MD; Redlich N; Tzeng SC; Kami K; Shelton L; Li A; Morgan Z; Bomalaski JS; Tsukamoto T; McConathy J; Michel LS; Held JM; Van Tine BA
    Cell Rep; 2017 Jan; 18(4):991-1004. PubMed ID: 28122247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.
    Li YY; Wu C; Chen SM; Shah SS; Wangpaichitr M; Feun LG; Kuo MT; Suarez M; Prince J; Savaraj N
    Oncotarget; 2016 Apr; 7(14):17665-80. PubMed ID: 26771234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
    Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
    Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.
    Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT
    Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
    Allen MD; Luong P; Hudson C; Leyton J; Delage B; Ghazaly E; Cutts R; Yuan M; Syed N; Lo Nigro C; Lattanzio L; Chmielewska-Kassassir M; Tomlinson I; Roylance R; Whitaker HC; Warren AY; Neal D; Frezza C; Beltran L; Jones LJ; Chelala C; Wu BW; Bomalaski JS; Jackson RC; Lu YJ; Crook T; Lemoine NR; Mather S; Foster J; Sosabowski J; Avril N; Li CF; Szlosarek PW
    Cancer Res; 2014 Feb; 74(3):896-907. PubMed ID: 24285724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas.
    Kunikane H; Zalupski MM; Ramachandran C; KuKuruga MA; Lucas D; Ryan JR; Krishan A
    Cytometry; 1997 Aug; 30(4):197-203. PubMed ID: 9298839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.